Cipla Launches Generic Sofosbuvir in India

Mar 26, 2015

Economic Times of India

Mumbai, India-based Cipla has announced the launch of a generic version of Gilead Sciences' Sofosbuvir for treating chronic Hepatitis C under the brand name Hepcvir, in India.

Cipla signed a non-exclusive licensing agreement with Gilead last September to manufacture and market chronic Hepatitis C medicines.

In January, India's patent controller had rejected Gilead Sciences' application for Sovaldi treatment, which allowed locally-based drug makers to sell lower-cost generic versions of the medicine.

Dr Reddy's and Hetero, Zydus Cadila and Natco Pharma have also signed non-exclusive agreements with Gilead to manufacture and sell its Hepatitis meds.

According to the Economic Times, around 12-18 million Indian patients are estimated to be infected with Hepatitis C.

Read the ET press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments